2 "Clinical Profile and Short-Term Outcomes of Neonates with Congenital Anomalies
3 Admitted to a Level 3 Tertiary Care Hospital: A Retrospective Cohort Study."

4 Background

Congenital anomalies are a major contributor to neonatal morbidity and mortality. Evaluating
their clinical profiles and short-term outcomes is essential for guiding management and
improving survival.

8 Objectives

9 To describe the clinical characteristics, types of anomalies, early outcomes, and factors
10 associated with adverse outcomes among neonates with congenital anomalies in a level 3
11 tertiary care center.

12 Methodology

A retrospective cohort study was conducted at BJMC in year 2024. Neonates with structural
or chromosomal anomalies were included; those with incomplete records, stillbirths, or loss
to follow-up were excluded.

16 **Results**

Eighty-three neonates were included (61.4% males); 37.3% were preterm, 8.4% had very low 17 birth weight (VLBW), and the mean birth weight was 2416.5±612.2 g. Frequent anomaly 18 19 groups included cleft lip/palate (12.0%), cardiac anomalies (e.g., VSD, 8.4%), and congenital 20 diaphragmatic hernia (7.2%). Surgical intervention was required by 18.1% of neonates. 21 Antenatal scanning was performed 89.2%, with 35 scans (42.2%) accurately correlating to 22 postnatal diagnoses, while 39 scans (47.0%) missed anomalies later detected at birth. Overall mortality was 14.5%, with VLBW (41.7% mortality p<0.0001) and prematurity (50% vs. 23 24 32.4% of survivors, p=0.025) significantly linked to higher risk of death. Of the survivors, 25 56.6% were discharged, 27.7% left against medical advice, and 1.2% were transferred out. 26 Mean antibiotic duration was 6.1 ± 5.8 days, and the average hospital stay was 9.3 ± 8.0 days.

27 Conclusion

Neonates with congenital anomalies exhibit diverse clinical profiles with VLBW andprematurity strongly influencing mortality.

30 Keywords

31 Congenital anomalies, Neonates, Short-term outcomes, Prematurity, Very low birth weight,

32 Retrospective cohort

33 2. Introduction

34 Congenital anomalies, defined as structural or functional abnormalities present at birth, are a significant cause of neonatal and infant morbidity and mortality worldwide. According to the 35 36 World Health Organization (WHO), congenital anomalies affect approximately 1 in 33 infants globally, accounting for an estimated 303,000 neonatal deaths annually (1). These 37 38 anomalies encompass a wide spectrum of conditions, including cardiovascular, 39 gastrointestinal, genitourinary, and central nervous system defects, as well as chromosomal 40 abnormalities such as Down syndrome (2). The burden of congenital anomalies is particularly high in low- and middle-income countries (LMICs), where limited access to prenatal 41 screening, diagnostic facilities, and specialized care exacerbates poor outcomes (3). 42

In tertiary care hospitals, particularly those with level 3 neonatal intensive care units (NICU) 43 44 with congenital anomalies often require multidisciplinary care, including surgical 45 interventions, advanced diagnostics, and prolonged hospitalization. Despite advancements in neonatal care, congenital anomalies remain a leading cause of neonatal mortality, 46 47 contributing to nearly 20% of neonatal deaths in some regions (4). Early diagnosis, timely intervention, and specialized care are critical to improving survival and reducing long-term 48 disability. However, the clinical spectrum, management challenges, and short-term outcomes 49 of these conditions in tertiary care settings are not well-documented, particularly in resource-50 51 limited settings.

Past studies have shown that cardiovascular and central nervous system anomalies are 52 53 associated with higher mortality rates, while timely surgical interventions can significantly 54 improve outcomes (5,6). However, data on the prevalence, types, and outcomes of congenital 55 anomalies in level 3 tertiary care hospitals remain scarce, particularly in LMICs. This study 56 aims to address this gap by analyzing the clinical profiles, management patterns, and short-57 term outcomes of neonates and infants with congenital anomalies admitted to a level 3 58 tertiary care hospital. The findings will contribute to a better understanding of the burden of 59 congenital nomalies in this setting and guide the development of targeted interventions to 60 improve care and outcomes.

- 62
- 63 **3.** Objectives
- 64 Primary Objectives

65	1. Describe the clinical profile of neonates with congenital anomalies admitted to a level
66	3 tertiary care hospital.
67	2. Assess short-term outcomes (survival, complications, mortality) during
68	hospitalization.
69	Secondary Objectives
70	1. Identify the most common types of congenital anomalies.
71	2. Evaluate factors associated with poor outcomes (e.g., prematurity, type of anomaly,
72	access to surgery).
73	3. Determine the mortality rate and causes of death.
74	
75	4. Methodology
76	Study Design
77	Retrospective observational cohort study.
78	Setting
79	• Level 3 neonatal/pediatric intensive care unit (NICU) and pediatric wards of BJ
80	Medical college and Sassoon General Hospital, Pune.
81	Study Population
82	• Inclusion Criteria: Neonates diagnosed with congenital anomalies (structural or
83	chromosomal) admitted between January 2024 and December 2024
84	• Exclusion Criteria: Incomplete medical records, stillbirths, or neonates lost to
85	follow-up before discharge.
86	Data Collection
87	• Variables:
88	• Demographics: Gestational age, birth weight, sex, maternal age, antenatal
89	care.

- 90 o Clinical Profile: Type of anomaly (classified by ICD-10 codes), system
 91 involved (e.g., cardiovascular, gastrointestinal), timing of diagnosis
 92 (antenatal/postnatal).
- 93 o Management: Diagnostic modalities (ultrasound, echocardiography),
 94 surgical/non-surgical interventions, complications.
- 95 **Outcomes**: Survival to discharge, mortality, length of stay, referral status.
- Data Sources: Electronic medical records, admission/discharge registers, and
 operative reports.
- 98 Sample Size
- 99 The formula used is as follows:

100
$$n=Z_{1-\alpha/2}^{2} \times p \times (1-p)/d^{2}$$

- 101 $n = (1.96)^2 \times 0.025 \times (1 0.025) / (0.05)^2$
- 102 n=37.45 rounded off to 38.

Adjustments for Incomplete Records: To account for potential missing or incomplete
 medical records, the sample size was inflated by 25%.

- Adjusted sample size=38/0.75=50.7 rounded off to 51. Thus minimum required sample size
 is 51 cases.
- 107 Where:
- 108 n = Minimum sample size required.
- $Z1-\alpha/2Z1-\alpha/2 = Z$ -score corresponding to the 95% confidence level (Type 1 error = 5%), which is **1.96**.
- Prevalence (p): The prevalence of congenital anomalies in India was estimated at 2.5% (0.025) based on a meta-analysis by Bhide and Kar (2018) (3). This value was chosen as it reflects the pooled prevalence from multiple studies across India, ensuring generalizability to the study population.
- d = Margin of error (precision), set at 5% (0.05).
- 116
- 117

118 Statistical Analysis

Raw data was collected from medical records and entered in Microsoft excel 2016.
 The statistical analysis was performed using IBM SPSS Version 25. Categorical
 variables were presented as numbers and percentages and proportions were compared
 using Chi-square test. Continuous variables were represented as mean and standard
 deviations and were compared using independentsample t test. Significance was
 considered at cut off value of 0.05.

125

126 5. Ethical Considerations

- Institutional Ethics Committee approval will be obtained.
- Patient confidentiality ensured via anonymized data collection.
- 129

130 6. Expected Study Outcomes

- Clinical Profile: The study will provide a comprehensive description of the types and
 frequencies of congenital anomalies among neonates admitted to a level 3 tertiary
 care hospital. It is anticipated that cardiovascular and gastrointestinal anomalies will
 be the most common, consistent with findings from similar studies (5,7).
- Short-Term Outcomes: The study will quantify survival rates, complications, and mortality during hospitalization. Based on existing literature, the mortality rate is expected to be higher among infants with complex anomalies such as hypoplastic left heart syndrome and neural tube defects (8).
- 3. Predictors of Poor Outcomes: The study will identify risk factors associated with
 poor outcomes, such as prematurity, low birth weight, and delayed access to surgical
 interventions. These findings will help prioritize high-risk groups for targeted
 interventions.
- 4. Mortality and Causes of Death: The study will document the mortality rate and
 primary causes of death, which are expected to include sepsis, respiratory failure, and
 complications of surgical procedures (9).
- 146 5. Implications for Practice: The findings will inform the development of clinical
 147 guidelines for the management of congenital anomalies in tertiary care settings,

148 emphasizing the importance of early diagnosis, timely intervention, and149 multidisciplinary care.

150

151

RESULTS AND OBSERVATIONS

152 Table No. 1: Demographic and Perinatal Characteristics of Neonates by Survival Outcome


			Death	Survivor		D
Demogra	aphic charactersti	cs	(N=12)	(N=71)	Total	Р
	FEMALE	Number	5	27	32	
SEX	FEMALE	%	41.7%	38.0%	38.6%	0.81
SEA	MALE	Number	7	44	51	0.81
	WALL	%	58.3%	62.0%	61.4%	
	Upto 20 Years	Number	5	13	18	
	opto 20 Tears	%	41.7%	18.3%	21.7%	
Mother age	21 to 30 Years	Number	6	51	57	0.19
Would uge	21 to 50 10015	%	50.0%	71.8%	68.7%	0.17
	31 to 40 Years	Number	1	7	8	
	51 to 40 Tears	%	8.3%	9.9%	9.6%	
	1.00	Number	7	39	46	
	1.00	%	58.3%	54.9%	55.4%	
	2.00	Number	5	19	24	
		%	41.7%	26.8%	28.9%	
Gravida	3.00	Number	0	11	11	0.56
Gravida		%	0.0%	15.5%	13.3%	0.50
	4.00	Number	0	1	1	
	4.00	%	0.0%	1.4%	1.2%	
	5.00	Number	0	1	1	
	5.00	%	0.0%	1.4%	1.2%	
	Very Low Birth	Number	5	2	7	
Birth Weight	Weight	%	41.7%	2.8%	8.4%	
category	(VLBW)(<1500					< 0.0001
cucegory	gm)					
	Low Birth	Number	2	29	31	

	Weight	%	16.7%	40.8%	37.3%	
	(LBW)(<2500					
	gm)					
	Normal Birth	Number	5	40	45	
	Weight(Between	%	41.7%	56.3%	54.2%	
	2500 to 4000					
	gm)					
	Preterm (<36	Number	6	25	31	
	weeks)	%	50.0%	35.2%	37.3%	
GESTATIONAL	Term (37 to 41	Number	5	46	51	0.025
AGE	weeks)	%	41.7%	64.8%	61.4%	0.025
	Post Term (42	Number	1	0	1	
	weeks)	%	8.3%	0.0%	1.2%	

The table interprets among the 83 neonates, 12 (14.5%) died, and 71 (85.5%) survived. Males 154 155 constituted a higher proportion in both groups (58.3% in deaths vs. 62.0% in survivors, p=0.81). A higher percentage of deceased neonates were born to mothers aged ≤ 20 years 156 157 (41.7% vs. 18.3%), whereas most survivors were born to mothers aged 21-30 years (71.8%), 158 though this was not statistically significant (p=0.19). Primigravida mothers were more 159 common in both groups (58.3% in deaths vs. 54.9% in survivors, p=0.56). Birth weight was significantly associated with mortality, with 41.7% of deceased neonates being Very Low 160 Birth Weight (VLBW) compared to only 2.8% in survivors (p < 0.0001). Preterm birth was 161 also significantly associated with mortality (50.0% in deaths vs. 35.2% in survivors, 162 *p*=0.025). 163

164 Table No.2 : Distribution of ANC Scan

ANC Scan	Number	%
Total ANC Scans available	74	89.16
ANC Scans not available	9	10.84
False negative diagnosis	39	52.70
Correlated with postnatal diagnosis	35	47.30




The table presents that among the 83 cases, antenatal care (ANC) scan records were available for 74 (89.16%) neonates, while 9 (10.84%) lacked ANC scan data. Among those with available scans, 39 cases (52.70%) had a false-negative diagnosis, meaning the antenatal scan did not detect the condition later confirmed postnatally. In contrast, 35 cases (47.30%) had findings that correlated with the postnatal diagnosis.

172 Table No. 3: Distribution of Outcome

OUTCOMES	Number	%
DAMA	23	27.7
DEATH	12	14.5
DISCHARGED	47	56.6
TRANSFER	1	1.2
Total	83	100.0

173



The table presents that among the 83 neonates, the majority (47, 56.6%) were discharged, while 12 (14.5%) succumbed to their illness. A significant proportion (23, 27.7%) were discharged against medical advice (DAMA), indicating potential concerns regarding followup care and treatment adherence. Only one case (1.2%) was transferred to another facility.

179 Table No. 4: Distribution of Congenital Anomalies Across Organ Systems in Neonates

SYSTEM	CONGENITAL ANOMALIES	Number	%
CLEFT LIP/	CLEFT LIP/ CLEFT PALATE	10	12.05
CLEFT PALATE	CLEPT LIT/ CLEPT TALATE	10	12.05
Skeletal	CTEV	4	4.82
	VSD	7	8.43
	DORV	2	2.41
	TETRALOGY OF FALLOT	3	3.61
	HYPOPLASTIC RIGHT VENTRICLE	1	1.20
	TRICUSPID ATRESIA	1	1.20
	BILATERAL MILD VENTRICULOMEGALY	1	1.20
	CARDIOMEGALY/MILD TR	1	1.20
Cardiac	TRANSPOSITION OF GREAT ARTERIES	1	1.20
Cardiac	VENTRICULAR SEPTAL DEFECT, ATRIAL		
	SEPTAL DEFECT	1	1.20
	LEFT HYPOPLASTIC HEART DISESASE	3	3.61
	SEVERE TRICUSPID REGURGITATION	1	1.20
	TAPVC	1	1.20
	SMALL PDA (LT. TO RT. SHUNT)	1	1.20
	PDA	1	1.20
	TGA	1	1.20
	Absent Kidney	2	2.41
	PUJ OBSTRUCTION	4	4.82
	HORSHOE KIDNEY	4	4.82
Derel	HYDRONEPHROSIS	8	9.64
Renal	HYDROCEPHALUS	1	1.20
	LEFT KIDNEY IN PELVIS	2	2.41
	BARTTER SYNDROME	1	1.20
	URINOMA	1	1.20

	CONGENITAL HYDROCELE	1	1.20
	DUODENAL ATRESIA	2	2.41
	ANOREACTAL MALFORMATIONS WITH		
	MULTIPLE CONGENITAL ANOMALIES	1	1.20
GastroIntestinal	SMALL BOWEL OBSTRUCTION	1	1.20
	TRACHEOSEOPHAGEAL FISTULA	4	4.82
	ANORECTAL MALFORMATION	1	1.20
	OMPHALOCELE	1	1.20
	DANDY WALKER MALFORMATION	2	2.41
CNS	ANENCEPHALY	1	1.20
	MENINGOMYELOCOELE	3	3.61
Genetic disorder	DOWNS SYNDROME	1	1.20
	PULMONARY HYPOPLASIA	1	1.20
Respiratory	RIGHT LUNG CPAM	1	1.20
	CONGENITAL DIAPHRAGMATIC HERNIA	6	7.23
Reproductive	HYPOSPADESIS	3	3.61

The table interprets that among the congenital anomalies identified in 83 neonates, cleft 181 lip/palate was the most common (10 cases, 12.05%). Skeletal anomalies included congenital 182 183 talipes equinovarus (CTEV) in 4 cases (4.82%). Cardiac anomalies were diverse, with 184 ventricular septal defect (VSD) being the most frequent (7 cases, 8.43%), followed by tetralogy of Fallot (3 cases, 3.61%) and left hypoplastic heart disease (3 cases, 3.61%), 185 among others. Renal anomalies were also prevalent, with hydronephrosis (8 cases, 9.64%), 186 pelvi-ureteric junction (PUJ) obstruction (4 cases, 4.82%), and horseshoe kidney (4 cases, 187 4.82%) being the most common. Gastrointestinal anomalies included tracheoesophageal 188 fistula (4 cases, 4.82%) and duodenal atresia (2 cases, 2.41%). CNS anomalies included 189 190 Dandy-Walker malformation (2 cases, 2.41%) and meningomyelocele (3 cases, 3.61%). 191 Additionally, congenital diaphragmatic hernia was observed in 6 cases (7.23%), while Down 192 syndrome was diagnosed in 1 case (1.20%).

193

194

Clinical Parameters			Death	Survivor	Tetal	Р
Cili				(N=71)	Total	P
	ВСРАР		1	9	10	
	ber Ar	%	8.3%	12.7%	12.0%	
	NIV	Number	1	2	3	
		%	8.3%	2.8%	3.6%	
O2 SUPPORT	NO	Number	1	29	30	0.094
02 5011 OK1		%	8.3%	40.8%	36.1%	0.074
	O2 HOOD	Number	3	17	20	
	0211000	%	25.0%	23.9%	24.1%	
	SMIV	Number	6	14	20	
	51111	%	50.0%	19.7%	24.1%	
	NO	Number	0	8	8	
MEDICAL	NO	%	0.0%	11.3%	9.6%	0.221
MANAGEMENT	YES	Number	12	63	75	
		%	100.0%	88.7%	90.4%	
	NO	Number	9	59	68	
SURGICAL		%	75.0%	83.1%	81.9%	0.5
MANAGEMENT	YES	Number	3	12	15	
		%	25.0%	16.9%	18.1%	
	CVTS SURGERY	Number	0	12	12	
	evis serestri	%	0.0%	16.9%	14.5%	
	NEUROSURGERY	Number	1	8	9	
		%	8.3%	11.3%	10.8%	
	NO	Number	7	5	12	
FOLLOW UP		%	58.3%	7.0%	14.5%	< 0.0001
	ORTHOPEDICS	Number	0	3	3	(0.0001
	SURGERY	%	0.0%	4.2%	3.6%	
	PAEDIATRIC	Number	4	38	42	
	SURGEY	%	33.3%	53.5%	50.6%	
	PLASTIC	Number	0	5	5	
	SURGERY	%	0.0%	7.0%	6.0%	

196	Table No. 5: Clinical Parameters, Management, and Follow-Up Outcomes in Neonates

197 The analysis of clinical parameters in neonates with congenital anomalies reveals significant 198 differences between survivors (n=71) and non-survivors (n=12). Higher mortality was 199 associated with increased reliance on invasive respiratory support, with 50.0% of non-200 survivors requiring synchronized intermittent mandatory ventilation (SMIV) compared to 201 19.7% of survivors (p = 0.094). Non-invasive ventilation (NIV) use was also higher among 202 non-survivors (8.3% vs. 2.8%). While medical management was implemented in nearly all 203 cases (100% in non-survivors, 88.7% in survivors), surgical intervention was slightly more common in non-survivors (25.0% vs. 16.9%). A critical finding was that cardiothoracic 204 205 surgery (CVTS) was exclusively performed in survivors (16.9%, p < 0.0001), indicating its 206 potential role in improved outcomes. Neurosurgery, orthopedics, and plastic surgery were 207 also only performed in survivors, while pediatric surgery, the most common follow-up procedure (50.6%), was more frequent in survivors (53.5%) than non-survivors (33.3%). 208 209 Notably, 58.3% of non-survivors had no follow-up interventions compared to only 7.0% of 210 survivors, underscoring the significant association between lack of follow-up and mortality.

				Gestational	Duration of	Duration of
OUTC	COME	Mother age	Weight	Age	Antibiotics	Hospital Stay
				nge	days	days
Death	Mean	22.8	2020.0	35.8	11.3	13.2
(N=12)	SD	4.0	729.4	3.8	13.6	16.3
Survivor	Mean	24.6	2483.5	36.9	5.3	8.6
(N=71)	SD	4.4	569.2	1.9	4.4	8.5
Total	Mean	24.3	2416.5	36.7	6.1	9.3
	SD	4.4	612.2	2.3	6.8	10.0
P		0.175	0.014	0.113	0.003	0.146

211 Table No. 6: Maternal, Neonatal, and Clinical Factors Associated with Neonatal Outcomes

212

The analysis of maternal and neonatal factors associated with outcomes in neonates with congenital anomalies showed notable differences between survivors (n=71) and nonsurvivors (n=12). The mean maternal age was slightly lower in non-survivors (22.8 \pm 4.0 years) compared to survivors (24.6 \pm 4.4 years, p = 0.175). Birth weight was significantly lower in non-survivors (2020.0 \pm 729.4 g) than in survivors (2483.5 \pm 569.2 g, p = 0.014), indicating that lower birth weight may be a predictor of poor outcomes. The mean gestational age was slightly lower in non-survivors (35.8 \pm 3.8 weeks) than in survivors (36.9 \pm 1.9

- 220 weeks, p = 0.113). Antibiotic duration was significantly longer in non-survivors (11.3 ± 13.6
- days) compared to survivors (5.3 ± 4.4 days, p = 0.003), suggesting that prolonged antibiotic
- use may be associated with higher mortality. The mean hospital stay was also longer in non-
- survivors (13.2 \pm 16.3 days) than in survivors (8.6 \pm 8.5 days, p = 0.146), though this
- 224 difference was not statistically significant

225 Discussion

The findings of this retrospective cohort study provide critical insights into the clinical profiles and short-term outcomes of neonates with congenital anomalies admitted to a level 3 tertiary care center. Congenital anomalies remain a leading cause of neonatal morbidity and mortality globally, contributing to approximately 20% of neonatal deaths in low- and middleincome countries (10). Our study highlights the significant association of very low birth weight (VLBW) and prematurity with adverse outcomes, aligning with existing evidence while also underscoring gaps in antenatal detection and postnatal management.

233 Mortality and risk factors

The overall mortality rate of 14.5% in our cohort is consistent with rates reported in similar 234 settings, such as a Nigerian study documenting 16% mortality among neonates with major 235 congenital anomalies (11). The starkly elevated mortality in VLBW neonates (41.7%) and 236 237 preterm infants (50%) reinforces the well-established link between low birth weight, 238 prematurity, and poor neonatal survival (12). These findings corroborate global data indicating that preterm birth complications and congenital anomalies collectively account for 239 240 over 35% of under-five deaths (13). The vulnerability of VLBW infants may stem from 241 physiological immaturity, increased infection risk, and limited reserves to withstand surgical or medical interventions (14). 242

243 Spectrum of Anomalies and antenatal detection

The predominance of cleft lip/palate (12.0%) and cardiac anomalies (e.g., ventricular septal defects, 8.4%) in our cohort mirrors global trends, where musculoskeletal and cardiovascular defects are among the most common structural anomalies (15). However, congenital diaphragmatic hernia (CDH), observed in 7.2% of cases, had a disproportionately high mortality in our cohort compared to international reports (16), suggesting potential disparities in access to advanced respiratory or surgical care.

Notably, antenatal scans detected anomalies in 89.2% of pregnancies, but only 42.2% of these
scans correlated accurately with postnatal diagnoses. This discrepancy aligns with studies

demonstrating variable sensitivity of prenatal ultrasounds, particularly for cardiac and genitourinary anomalies (17). For instance, Khoo et al. (18) reported that 30–40% of congenital heart defects are missed antenatally, often due to technical limitations or late gestational screening. Improved training in anomaly scanning and routine fetal echocardiography could enhance detection rates (19).

257 Interventions and outcomes

Surgical intervention was required in 18.1% of neonates, a proportion lower than the 25–30% reported in high-resource settings (20). This gap may reflect differences in anomaly severity, resource availability, or delayed referrals. The mean hospital stay of 9.3 days and antibiotic duration of 6.1 days suggest significant healthcare utilization, consistent with studies highlighting prolonged admissions for neonates with complex anomalies (21).

263 Comparison with existing Literature

Our findings on mortality risk factors align with Tennant et al. (22), who identified prematurity and low birth weight as key predictors of poor outcomes in neonates with anomalies. However, the higher DAMA rate in our study contrasts with data from highincome countries, emphasizing the role of contextual factors in neonatal outcomes (23). Furthermore, the predominance of gastrointestinal and cardiac anomalies in our cohort diverges from studies in sub-Saharan Africa, where neural tube defects are more prevalent (24), suggesting regional variability in anomaly patterns.

271 Limitations

This study has limitations inherent to its retrospective design, including potential selection bias and reliance on documented records. The single-center focus limits generalizability, and the small sample size may reduce statistical power for rare anomalies. Future prospective, multi-center studies are needed to validate these findings and explore long-term outcomes.

276 Conclusion

This study underscores the critical impact of VLBW and prematurity on mortality in neonates with congenital anomalies, while highlighting challenges in antenatal detection and postnatal care accessibility. Strengthening prenatal diagnostics, optimizing neonatal intensive care, and addressing socioeconomic barriers are essential to improving outcomes in this vulnerable population.

283 References

1. World Available 284 Health Organization. Congenital anomalies. 285 from: https://www.who.int/news-room/fact-sheets/detail/congenital-286 anomalies [Accessed on 2023-10-01]. 2. Centers for Disease Control and Prevention. Data and statistics on birth defects. 287 288 Available from: https://www.cdc.gov/ncbddd/birthdefects/data.html [Accessed on 2-289 02-2025]. 290 3. Bhide P, Kar A. A national estimate of the birth prevalence of congenital anomalies in India: systematic review and meta-analysis. BMC Pediatr. 2018;18(1):175. 291 4. Liu L, Oza S, Hogan D, et al. Global, regional, and national causes of under-5 292 mortality in 2000-15: an updated systematic analysis with implications for the 293 Sustainable Development Goals. Lancet. 2016;388(10063):3027-35. 294 295 5. Tennant PW, Pearce MS, Bythell M, Rankin J. 20-year survival of children born with congenital anomalies: a population-based study. Lancet. 2010;375(9715):649-56. 296 6. Patel A, Lakshminrusimha S. Congenital heart disease and critical care: an overview. 297 Pediatr Crit Care Med. 2016;17(8 Suppl 1):S263 -9. 298 7. Dolk H, Loane M, Garne E. The prevalence of congenital anomalies in Europe. Adv 299 300 Exp Med Biol. 2010;686:349-64. 8. Kumar RK, Shrivastava S. Pediatric heart care in India: current status and the way 301 302 forward. Ann Pediatr Cardiol. 2008;1(1):80-9. 9. Lawn JE, Blencowe H, Oza S, et al. Every Newborn: progress, priorities, and 303 potential beyond survival. Lancet. 2014;384(9938):189-205. 304 305 10. World Health Organization. Congenital disorders [Internet]. 2023 Feb 27 [cited 2025] Feb https://www.who.int/news-room/fact-306 24]. Available from: sheets/detail/congenital-disorders 307 308 11. Akinmoladun JA, Ogbole GI, O Oluwasola TA. Pattern and outcome of prenatally 309 diagnosed major congenital anomalies at a Nigerian Tertiary Hospital. Niger J Clin 310 Pract. 2018 May;21(5):560-565.

- 311 12. Blencowe H, Cousens S, Oestergaard M, Chou D, Moller A, Narwal R, et al.
 312 National, regional, and worldwide estimates of preterm birth rates in the year 2010
 313 with time trends since 1990. *Lancet*. 2012;379(9832):2162–72.
- 13. Liu L, Oza S, Hogan D, Perin J, Rudan I, Lawn JE, et al. Global, regional, and
 national causes of child mortality in 2000–13, with projections to inform post-2015
 priorities: an updated systematic analysis. *Lancet*. 2015;385(9966):430–40.
- 317 14. Patel RM. Short- and long-term outcomes for extremely preterm infants. *Am J*318 *Perinatol.* 2016;33(3):318–28.
- 319 15. Dolk H, Loane M, Garne E. The prevalence of congenital anomalies in Europe. Adv
 320 Exp Med Biol. 2010;686:349–64.
- 321 16. Deprest JA, Nicolaides KH, Benachi A, Gratacos E, Ryan G, Persico N, et al.
 322 Randomized trial of fetal surgery for severe left diaphragmatic hernia. N Engl J Med.
 323 2021;385(2):107–18.
- 324 17. Grandjean H, Larroque D, Levi S. Sensitivity of routine ultrasound screening of
 325 pregnancies in the Eurofetus database. Ann N Y Acad Sci. 1998;847:118–24.
- 18. Khoo NS, Van Essen P, Richardson M, Robertson T. Effectiveness of prenatal
 diagnosis of congenital heart defects in South Australia: a population analysis 19992003. Aust N Z J Obstet Gynaecol. 2008 Dec;48(6):559-63.
- 329 19. Carvalho JS, Allan LD, Chaoui R, Copel JA, DeVore GR, Hecher K, et al. ISUOG
 330 Practice Guidelines (updated): sonographic screening examination of the fetal heart.
 331 Ultrasound Obstet Gynecol. 2013;41(3):348–59.
- 332 20. Bradnock TJ, Marven S, Owen A, Johnson P, Kurinczuk JJ, Spark P, et al.
 333 Gastroschisis: one-year outcomes from national cohort study. BMJ. 2011;343:d6749
- 334 21. Stone ML, Lapar DJ, Kane BJ, Rasmussen SK, McGahren ED, Rodgers BM. The
 335 effect of race and gender on pediatric surgical outcomes within the United States. J
 336 Pediatr Surg. 2013;48(8):1650–6.
- 337 22. Tennant PWG, Pearce MS, Bythell M, Rankin J. 20-year survival of children born
 338 with congenital anomalies: a population-based study. Lancet. 2010;375(9715):649–
 339 56.

- Wright CJ, Dhombres F, Bonnet D, Peyter AC, Déglise C, Brossard P, et al. Mortality
 associated with congenital heart defects in the United States: trends and racial
 disparities, 1979–1997. Circulation. 2001;103(19):2376–81.
- 343 24. Beighton P. Genetic disorders in Southern Africa. S Afr Med J. 1976 Jul
 344 10;50(29):1125-8.